| Authors: |
Kroenke MA; Clinical Immunology, Amgen, Thousand Oaks, CA, United States., Manning MS; Translational Safety & Bioanalytical Sciences, Amgen, Thousand Oaks, CA, United States., Zuch de Zafra CL; Translational Safety & Bioanalytical Sciences, Amgen, South San Francisco, CA, United States., Zhang X; Clinical Pharmacology, Modeling, and Simulation, Amgen, South San Francisco, CA, United States., Cook KD; Pharmacokinetics and Drug Metabolism, Amgen, South San Francisco, CA, United States., Archer M; Global Safety, Amgen, Thousand Oaks, CA, United States., Lolkema MP; Early Development, Amgen, Thousand Oaks, CA, United States., Wang J; Translational Safety & Bioanalytical Sciences, Amgen, Thousand Oaks, CA, United States., Hoofring S; Translational Safety & Bioanalytical Sciences, Amgen, Thousand Oaks, CA, United States., Saini G; Translational Safety & Bioanalytical Sciences, Amgen, Thousand Oaks, CA, United States., Aeffner F; Translational Safety & Bioanalytical Sciences, Amgen, South San Francisco, CA, United States., Ahern E; Medical Oncology, Monash Health, Clayton, VIC, Australia., Cabanas EG; Research Unit, Hospital Universitario Vall d'Hebron, Barcelona, Spain., Govindan R; Division of Hematology and Oncology, Washington University Medical School, St. Louis, MO, United States., Hui M; Chris O'Brien Lifehouse, Camperdown, NSW, Australia., Gupta S; Translational Safety & Bioanalytical Sciences, Amgen, Thousand Oaks, CA, United States., Mytych DT; Clinical Immunology, Amgen, Thousand Oaks, CA, United States. |
